| 1 |
32297127 | Immune Reconstitution Therapy or Continuous Immunosuppression for the Management of Active Relapsing-Remitting Multiple Sclerosis Patients? A Narrative Review. | 2020 Jun |
1 |
| 2 |
32645640 | The ocrelizumab phase II extension trial suggests the potential to improve the risk: Benefit balance in multiple sclerosis. | 2020 Sep |
1 |
| 3 |
22712014 | Two Cases of Cerebral Involvement in Malignant Lymphoma (CD20+) That Responded to Combination Therapy with Rituximab and Cladribine. | 2012 May |
1 |
| 4 |
10970137 | Bone marrow remission of hairy cell leukaemia induced by rituximab (anti-CD20 monoclonal antibody) in a patient refractory to cladribine. | 2000 Jun |
1 |